[Clinical trial of ventax (long-acting theophylline) in chronic obstructive bronchitis].
Clinical evidence obtained on efficacy of a new long-acting theophylline ventax in chronic obstructive bronchitis demonstrates that it has advantages over theophylline, produces positive changes in the patients' external respiration, dyspnea severity, auscultatory parameters, subjective response, is well tolerated and highly effective against chronic obstructive bronchitis. Side effects of ventax are outlined.
Nikitina
A V
AV
State Medical Academy of NN Burdenko, Voronezh.
Karpukhina
E P
EP
Lapygina
M V
MV
Evstratov
A I
AI
D000328:Adult; D000368:Aged; D001991:Bronchitis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D004417:Dyspnea / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D012129:Respiratory Function Tests; D013806:Theophylline / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D001993:Bronchodilator Agents; D013806:Theophylline
Opyt klinicheskogo primeneniia preparata ventaks (prolongirovannyi teofillin) pri lechenii bol'nykh khronicheskim obstruktivnym bronkhitom.